medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2007, Número 2

<< Anterior Siguiente >>

Rev Inst Nal Enf Resp Mex 2007; 20 (2)


Tabaquismo y diabetes

Fabián MMG, Cobo AC

Idioma: Español
Referencias bibliográficas: 64
Paginas: 149-158
Archivo PDF: 102.77 Kb.


RESUMEN

La nicotina, una de las drogas que contiene el tabaco, es una de las sustancias más adictivas que se conocen; entre otros efectos, participa en la producción de neoplasias malignas de pulmón, boca, garganta y vejiga. También eleva los niveles de colesterol y glucosa, lo que puede resultar en mayores posibilidades de padecer Diabetes mellitus y en descontrol metabólico de la enfermedad.
El tabaquismo incrementa la severidad y frecuencia de las complicaciones micro y macrovasculares de los pacientes con diabetes que tienen mayor dependencia del tabaco y tres veces más probabilidades de morir de enfermedades cardiovasculares.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bjartveit K, Tverdal A. Health consequences of smoking l-4 cigarettes per day. Tob Control 2005;14:315-320.

  2. Peñafiel MR, García RV, Moreno PF, González RJF, Ros DE. Resultados sobre la isquemia crónica de los miembros inferiores: estudio angiogeriátrico Granada-90 (segunda parte). Angiología 1992;44:102-146.

  3. Cruz OY, Arrastía AME, Sánchez SR, Lugones BM, Vázquez SM. Estudio de algunos factores maternos asociados con el bajo peso. Rev Cubana Obstet Ginecol 1998;24:54-77.

  4. Gestión de la dislipidemia en adultos con diabetes. Recomendaciones sobre Procedimientos Clínicos 2001 de la Asociación Americana de la Diabetes. Diabetes Care 2001;24 Supl 1:1-133.

  5. Segura FA, Rius MG. Factores de riesgo cardiovascular en una población rural de Castilla-La Mancha. Rev Esp Cardiol 1999;52:577-588.

  6. Haire-Joshu D, Glasgow RE, Tibbs TL; American Diabetes Association. Smoking and diabetes. Diabetes Care 2003;26 Suppl 1:89-90.

  7. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999;22:1887-1898.

  8. Estrategias para reducir la morbilidad y mortalidad de la diabetes. Rev Panam Salud Pública 2001;10:354-357.

  9. Giachetto G, Martínez M, Montaño A. Infecciones respiratorias agudas bajas de causa viral en niños menores de dos años. Posibles factores de riesgo de gravedad. Arch Pediatr Urug 2001;72:206-210.

  10. Marsiglia GI. Enfermedad tiroidea asociada a otras enfermedades sistémicas. Gac Méd Caracas 2005; 113:453-465.

  11. Tabaco, factores genéticos y riesgo de artritis reumatoide (2006, agosto 3). Disponible en: db.doyma.es/cgi-bin/wdbcgi.exe/doyma/press.plantilla?ident= 45619

  12. Solberg LI, Desai JR, O’Connor PJ, Biship DB, Devlin HM. Diabetic patients who smoke: are they different? Ann Fam Med 2004;2:26-32.

  13. Muhlhauser I. Cigarette smoking and diabetes: an update. Diabet Med 1994;11:336-343.

  14. Arvanitakis Z, Wilson R, Bienias J, Evans D, Bennett D. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661-666.

  15. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.

  16. Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 1996;31 Suppl:3-13.

  17. Malarcher AM, Ford ES, Nelson DE, et al. Trends in cigarette smoking and physicians’ advice to quit smoking among people with diabetes in the U.S. Diabetes Care 1995;18:694-697.

  18. Savage PJ, Narayan KM. Reducing cardiovascular complications of type 2 diabetes. A complex but achievable and affordable task. Diabetes Care 2000;23:1119-1123.

  19. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352;837-853.

  20. Boyle RG, O’Connor P, Pronk N, Tan A. Health behaviors of smokers, ex-smokers, and never smokers in an HMO. Prev Med 2000;31(2 Pt 1):177-182.

  21. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.

  22. Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002;121:932-941.

  23. Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabet Med 2000;17:755-761.

  24. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanent Diabetes registry. Am J Med 2001;111:1-9.

  25. Targher G. ¿Cómo influye el tabaco sobre la sensibilidad a la insulina? Número especial. Diabetes Voice 2005;50:23-25.

  26. Metz CN, Gregersen PK, Malhotra AK. Metabolism and biochemical effects of nicotine for primary care providers. Med Clin North Am 2004;88:1399-1413.

  27. Tziomalos K, Charsoulis F. Endocrine effects of tobacco smoking. Clin Endocrinol (Oxf) 2004;61:664-674.

  28. Targher G, Alberiche M, Zenene MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:3619-1324.

  29. Bjorntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabet Med 1999;16:373-383.

  30. Axelsson T, Jansson PA, Smith U, Eliasson B. Nicotine infusion acutely impairs insulin sensitivity in type 2 diabetic patients but not in healthy subjects. J Intern Med 2001;249:539-544.

  31. Yugar-Toledo JC, Tanus-Santos JE, Sabha M, et al. Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. Chest 2004;125:823-830.

  32. Nilsson PM, Gudbjornsdottir S, Eliasson B, Cederholm J; Steering Committee of the Swedish National Diabetes Register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes data from the National Diabetes Register in Sweden. Diabetes Metab 2004;30:261-268.

  33. Muhlhauser I, Bender R, Bott U, et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 1996;13:536-543.

  34. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241: 2035-2038.

  35. Kim HK, Bae JW, Chung JW, et al. Differences in the immediate effects of smoking on left ventricular diastolic function between healthy volunteers and patients with type 2 diabetes mellitus. J Am Soc Echocardiogr 2005;18:320-325.

  36. Cambios ecocardiográficos en pacientes sanos y en fumadores. Memorias del Congreso de Tabaquismo. Enero, 2000. Islas Canarias, España.

  37. Mitchell BD, Hawthorne VM, Vinik AI. Cigarette smoking and neuropathy in diabetic patients. Diabetes Care 1990;13:434-437.

  38. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-R353.

  39. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rôssner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397.

  40. Lutz B. El sistema endocannabinoide: vínculo entre metabolismo y tabaquismo: número especial. Diabetes Voice 2005;50:33-35.

  41. Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005;312:875-883.

  42. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.

  43. England LJ, Levine RJ, Qian C, et al. Glucose tolerance and risk of gestational diabetes mellitus in nulliparous women who smoke during pregnancy. Am J Epidemiol 2004;160:1205-1213.

  44. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62-67.

  45. Montgomery SM, Ekbom A. Smoking during pregnancy and diabetes mellitus in a British longitudinal birth cohort. BMJ 2002;324:26-27.

  46. Von Kries R, Toschke AM, Koletzko B, Slikker W Jr. Maternal smoking during pregnancy and childhood obesity. Am J Epidemiol 2002;156:954-961.

  47. Toschke AM, Montgomery SM, Pfeiffer U, von Kries R. Early intrauterine exposure to tobacco-inhaled products and obesity. Am J Epidemiol 2003; 58: 1068-1074.

  48. Ravelli AC, van der Meulen JH, Osmond C, Barker DJ, Bleker OP. Obesity at the age of 50 y in men and women exposed to famine prenatally. Am J Clin Nutr 1999;70:811-816.

  49. Mortensen EL, Michaelsen KF, Sanders SA, Reinisch JM. A dose-response relationship between maternal smoking during late pregnancy and adult intelligence in male offspring. Paediatr Perinat Epidemiol 2005;19:4-11.

  50. Toschke AM, Ehlin AG, von Kries R, Ekbom A, Montgomery SM. Maternal smoking during pregnancy and appetite control in offspring. J Perinat Med 2003; 31:251-256.

  51. Vineis P, Airoldi L, Veglia P, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 2005;330:277.

  52. Wilson SE, Kahn RS, Khoury J, Lanphear BP. Racial differences in exposure to environmental tobacco smoke among children. Environ Health Perspect 2005;113:362-367.

  53. Gómez-Restrepo C, Bohórquez A, Pinto DM, Gil LJFA, Rondón S, Díaz-Granados N. Prevalencia de depresión y factores asociados con ella en la población colombiana. Rev Panam Salud Publica 2004;16:378-386.

  54. Peters A. Diabetes care and treatment of tobacco use. In: Anderson B, Rubin R, editors. Practical psychology for diabetes clinicians practical. 2nd ed. USA: American Diabetes Association; 2002.p.103-112.

  55. Hill S, Blakely T, Kawachi I, Woodward A. Mortality among "never smokers" living with smokers: two cohort studies, 1981-4 and 1996-9. BMJ 2004;328: 988-989.

  56. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ 2002;325:188.

  57. Schroeder SA. What to do with a patient who smokes. JAMA 2005;294:482-487.

  58. Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 2003;45:429-441.

  59. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994;271:1940-1947.

  60. Despres JP, Tremblay A, Nadeau A, Bouchard C. Physical training and changes in regional adipose tissue distribution. Acta Med Sand Suppl 1988;723:205-212.

  61. Tremblay A, Despres JP, Leblanc C, et al. Effect or intensity of physical activity on body fatness and fat distribution. Am J Clin Nutr 1990;51:153-157.

  62. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-1202.

  63. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-1568.

  64. Gordon T, Kannel WB, Dawber TR, McGee D. Changes associated with quitting cigarette smoking: the Framingham Study. Am Heart J 1975;90:322-328.




2020     |     www.medigraphic.com